Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBIT (2022 - 2025)

Historic EBIT for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $43.0 million.

  • Indivior Pharmaceuticals' EBIT rose 2285.71% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.0 million, marking a year-over-year increase of 44047.62%. This contributed to the annual value of -$23.0 million for FY2024, which is 8486.84% up from last year.
  • Indivior Pharmaceuticals' EBIT amounted to $43.0 million in Q3 2025, which was up 2285.71% from $72.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' 5-year EBIT high stood at $72.0 million for Q2 2025, and its period low was -$258.0 million during Q4 2022.
  • In the last 4 years, Indivior Pharmaceuticals' EBIT had a median value of $56.5 million in 2022 and averaged $4.6 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' EBIT plummeted by 42678.57% in 2023 and then soared by 16101.69% in 2025.
  • Quarter analysis of 4 years shows Indivior Pharmaceuticals' EBIT stood at -$258.0 million in 2022, then skyrocketed by 123.26% to $60.0 million in 2023, then dropped by 23.33% to $46.0 million in 2024, then fell by 6.52% to $43.0 million in 2025.
  • Its last three reported values are $43.0 million in Q3 2025, $72.0 million for Q2 2025, and $66.0 million during Q1 2025.